Affiliation:
1. Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens,
New York 11439, United States
Abstract
Background:
DNA topoisomerases are a class of enzymes that play a critical role in fundamental
biological processes of replication, transcription, recombination, repair and chromatin remodeling.
Amsacrine (m-AMSA), the best-known compound of 9-anilinoacridines series, was one
of the first DNA-intercalating agents to be considered a Topoisomerase II inhibitor.
Objective:
A series of sulfur-containing 9-anilinoacridines related to amsacrine were synthesized
and evaluated for their anticancer activity.
Methods:
using the Human topoisomerase II Assay kit, and flow cytometry was used to evaluate
the effects on the cell cycle of K562 cells. Molecular docking was performed using the
Schrödinger Maestro program.
Results:
Compound 36 was found to be the most cytotoxic of the sulfide series against SW620,
K562, and MCF-7. The limited SAR suggested the importance of the methansulfonamidoacetamide
side chain functionality, the lipophilicity, and the relative metabolic stability of 36 in contributing
to the cytotoxicity. Topoisomerase II α inhibitory activity appeared to be involved in the
cytotoxicity of 36 through the inhibition of decatenation of kinetoplast DNA (kDNA) in a concentration-
dependent manner. Cell cycle analysis further showed Topo II inhibition through the accumulation
of K562 cells in the G2/M phase of the cell cycle. The docking of 36 into the Topo II α-DNA
complex suggested that it may be an allosteric inhibitor of Topo II α.
Conclusion:
Compound 36 exhibits anticancer activity by inhibiting topoisomerase II, and it could
further be evaluated in in vivo models.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),Cancer Research,Drug Discovery,Oncology,General Medicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献